Innate immunity in inflammatory bowel disease

被引:79
作者
Yamamoto-Furusho, Jesus K.
Podolsky, Daniel K.
机构
[1] Massachusetts Gen Hosp, Gastroenterol Unit, Boston, MA 02114 USA
[2] Massachusetts Gen Hosp, Ctr Study Inflammatory Bowel Dis, Harvard Med Sch, Gastroenterol Unit, Boston, MA 02114 USA
关键词
innate; immunity; toll-like receptors; inflammatory bowel disease;
D O I
10.3748/wjg.v13.i42.5577
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The human intestinal tract is home to an enormous bacterial flora. The host defense against microorganisms can be divided into innate and adaptive immunity. The former is the most immediate line of response to immunologic challenges presented by bacteria, viruses, and fungi. The mucosal immune system has evolved to balance the need to respond to pathogens while co-existing with commensal bacteria and food antigens. In inflammatory bowel disease (IBD), this hyporesponsiveness or tolerance breaks down and inflammation supervenes driven by the intestinal microbial flora. Bacteria contain compounds and are recognized by a variety of receptors, including Toll-like receptors (TLRs) and NODs (a family of intracellular bacterial sensors) and are potent stimuli of innate immune responses. Several mutations in these receptors have been associated with development of IBD. (c) 2007 WJG. All rights reserved.
引用
收藏
页码:5577 / 5580
页数:4
相关论文
共 37 条
[1]
Pathogen recognition and innate immunity [J].
Akira, S ;
Uematsu, S ;
Takeuchi, O .
CELL, 2006, 124 (04) :783-801
[2]
TLR4 mutations are associated with endotoxin hyporesponsiveness in humans [J].
Arbour, NC ;
Lorenz, E ;
Schutte, BC ;
Zabner, J ;
Kline, JN ;
Jones, M ;
Frees, K ;
Watt, JL ;
Schwartz, DA .
NATURE GENETICS, 2000, 25 (02) :187-+
[3]
Arnott IDR, 2005, GUT, V54, P308
[4]
Differential alteration in intestinal epithelial cell expression of Toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease [J].
Cario, E ;
Podolsky, DK .
INFECTION AND IMMUNITY, 2000, 68 (12) :7010-7017
[5]
The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease [J].
Cuthbert, AP ;
Fisher, SA ;
Mirza, MM ;
King, K ;
Hampe, J ;
Croucher, PJP ;
Mascheretti, S ;
Sanderson, J ;
Forbes, A ;
Mansfield, J ;
Schreiber, S ;
Lewis, CM ;
Mathew, CG .
GASTROENTEROLOGY, 2002, 122 (04) :867-874
[6]
High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease [J].
Darfeuille-Michaud, A ;
Boudeau, J ;
Bulois, P ;
Neut, C ;
Glasser, AL ;
Barnich, N ;
Bringer, MA ;
Swidsinski, A ;
Beaugerie, L ;
Colombel, JF .
GASTROENTEROLOGY, 2004, 127 (02) :412-421
[7]
Treatment of active Crohn's disease with recombinant human granulocyte-macrophage colony-stimulating factor [J].
Dieckgraefe, BK ;
Korzenik, JR .
LANCET, 2002, 360 (9344) :1478-1480
[8]
Crohn's disease: a defensin deficiency syndrome? [J].
Fellermann, K ;
Wehkamp, J ;
Herrlinger, KR ;
Stange, EF .
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2003, 15 (06) :627-634
[9]
Cytosolic flagellin requires Ipaf for activation of caspase-1 and interleukin 1β in salmonella-infected macrophages [J].
Franchi, Luigi ;
Amer, Amal ;
Body-Malapel, Mathilde ;
Kanneganti, Thirumala-Devi ;
Ozoren, Nesrin ;
Jagirdar, Rajesh ;
Inohara, Naohiro ;
Vandenabeele, Peter ;
Bertin, John ;
Coyle, Anthony ;
Grant, Ethan P. ;
Nunez, Gabriel .
NATURE IMMUNOLOGY, 2006, 7 (06) :576-582
[10]
Deficient host-bacteria interactions in inflammatory bowel disease?: The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn's disease and ulcerative colitis [J].
Franchimont, D ;
Vermeire, S ;
El Housni, H ;
Pierik, M ;
Van Steen, K ;
Gustot, T ;
Quertinmont, E ;
Abramowicz, M ;
Van Gossum, A ;
Devière, J ;
Rutgeerts, P .
GUT, 2004, 53 (07) :987-992